FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379141146> ?p ?o ?g. }

• W4379141146 abstract "Kimura and colleagues recently published an interesting report describing the occurrence of autoimmune hemolytic anemia (AIHA) and pure red cell aplasia (PRCA) in the setting of coronavirus disease 2019 (COVID-19) [[1]Kimura H. Furukawa M. Shiga Y. et al.Exacerbation of autoimmune hemolytic anemia associated with pure red cell aplasia after COVID-19: a case report.J Infect Chemother. 2023; https://doi.org/10.1016/j.jiac.2023.04.002Abstract Full Text Full Text PDF Scopus (0) Google Scholar]. This combination of immune phenomena has rarely been described; however, the co-occurrence of multiple autoimmune disorders in the setting of COVID-19 is not unexpected given the immune dysregulation observed in a substantial percentage of patients with this infection. Nevertheless, the diagnosis of AIHA secondary to COVID-19, while not novel [[2]Jacobs J.W. Booth G.S. COVID-19 and immune-mediated RBC destruction.Am J Clin Pathol. 2022; 157: 844-851https://doi.org/10.1093/ajcp/aqab210Crossref PubMed Scopus (19) Google Scholar], is still rare, and sufficient laboratory data must be presented to definitively conclude this unusual event. The authors reportedly diagnosed the patient in question with warm AIHA on the basis of abnormal hemolytic biomarkers and a direct antiglobulin test (DAT) positive for IgG. Unfortunately, aside from the reported “positive DAT (IgG-mediated)”, the authors provide no definitive evidence to conclude this was an immune-mediated hemolytic process. Importantly, the authors fail to describe the testing methodology employed for the DAT, which is crucial in assessing potential immune-mediated processes, as differing methodologies (e.g., tube, gel, solid phase, flow cytometry) vary significantly in both their sensitivity and specificity [[3]Jäger U. Barcellini W. Broome C.M. et al.Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting.Blood Rev. 2020; 41100648https://doi.org/10.1016/j.blre.2019.100648Crossref PubMed Scopus (185) Google Scholar]. This variability can often lead to false positive or false negative results. Additionally, the authors failed to report any additional immunohematologic tests or results, including plasma or elution studies. This is important, as a clinically significant warm autoantibody would typically show pan-reactivity in a patient's plasma when tested against donor reagent red blood cells (RBCs), and would be able to be eluted from the patient's RBCs and similarly react with all reagent RBCs. The absence of reactivity in plasma, and particularly in the eluate, would suggest an alternative cause of immune-mediated hemolysis such as a drug-induced process. Moreover, the authors failed to comment on recent transfusion history or medication use, both of which could also result in a positive DAT, and similarly could potentially mediate hemolysis via a drug-induced or delayed alloantibody-mediated hemolytic process if the patient had undergone recent transfusion. Another point to consider is that a significant proportion of individuals may display a positive DAT at baseline without evidence of hemolysis, including a small fraction of healthy blood donors (0.1%) and a larger percentage of hospitalized patients (up to 15%) [[2]Jacobs J.W. Booth G.S. COVID-19 and immune-mediated RBC destruction.Am J Clin Pathol. 2022; 157: 844-851https://doi.org/10.1093/ajcp/aqab210Crossref PubMed Scopus (19) Google Scholar]. Most notably, up to 50% of patients with COVID-19 may have a positive DAT without an underlying hemolytic process [[4]Berzuini A. Bianco C. Paccapelo C. et al.Red cell-bound antibodies and transfusion requirements in hospitalized patients with COVID- 19.Blood. 2020; 136: 766-768Crossref PubMed Google Scholar]. Causes of false-positive DATs, or positive DATs without hemolysis include various conditions that predispose patients to increased binding of immunoglobulins to RBCs, including hematologic disorders such as sickle cell disease [[5]Parker V. Tormey C.A. The direct antiglobulin test: indications, interpretation, and pitfalls.Arch Pathol Lab Med. 2017; 141: 305-310https://doi.org/10.5858/arpa.2015-0444-RSCrossref PubMed Scopus (53) Google Scholar]. Further, conditions with elevated serum immunoglobulin levels are associated with an increased incidence of positive DATs [[5]Parker V. Tormey C.A. The direct antiglobulin test: indications, interpretation, and pitfalls.Arch Pathol Lab Med. 2017; 141: 305-310https://doi.org/10.5858/arpa.2015-0444-RSCrossref PubMed Scopus (53) Google Scholar]. Other causes include high serum protein, antiphospholipid antibodies, reticulocytosis, medications including intravenous immune globulin, and certain infectious agents [[5]Parker V. Tormey C.A. The direct antiglobulin test: indications, interpretation, and pitfalls.Arch Pathol Lab Med. 2017; 141: 305-310https://doi.org/10.5858/arpa.2015-0444-RSCrossref PubMed Scopus (53) Google Scholar]. In this context, it is important to report the strength of the DAT reaction, which is typically graded on a 1+ to 4+ scale, while microscopic (i.e., m) or weakly-positive (i.e., w+) DATs are usually considered negative. Although variability among both technologists and laboratories likely exists in interpreting DAT strength, a positive DAT secondary to non-specific immunoglobulin or protein binding generally displays weaker agglutination. Conversely, the opposite is not necessarily true (i.e., a ‘true’ DAT is not always 4+); however, some authors have shown that DAT strength may indeed correlate with the presence of in vivo hemolysis [[6]Kerkar A.S. Bhagwat S.N. Sharma J.H. A study of clinical and serological correlation of positive direct antiglobulin test in blood bank at a tertiary care center.J Lab Phys. 2022; 14: 223-230https://doi.org/10.1055/s-0041-1741442Crossref PubMed Google Scholar]. Thus, the DAT reactivity strength is a helpful component in assessing its significance when evaluating patients for potential autoimmune hemolysis. All of these considerations must be taken into account when assessing a patient for a potential immune-mediated hemolytic condition, as the DAT is simply designed to determine if immunoglobulin G (IgG) and/or complement (C3) is bound to an individual's RBCs. The DAT itself does not automatically implicate an autoimmune hemolytic process, and care should be taken to provide additional evaluation and contextual information in these cases. Nevertheless, I do not necessarily disagree that the authors' case represents AIHA in the setting of mild COVID-19 without significant inflammation; however, this is not novel, as we have previously described patients with significant immunosuppression and an absence of underlying inflammation having the ability to develop severe AIHA [[7]Jacobs J.W. Gisriel S.D. SARS-CoV-2-associated warm autoimmune haemolytic anaemia in an immunosuppressed patient: the trend continues.Transfus Med. 2022; 32: 525-526https://doi.org/10.1111/tme.12928Crossref PubMed Scopus (0) Google Scholar]. Thus, I concur with the authors that additional biologic mechanisms of autoimmunity and pathogen-mediated cross-reactivity are likely contributing factors, and further investigation into these mechanisms will undoubtedly elucidate novel etiologies of autoimmune phenomena. In summary, this case contributes to the literature regarding COVID-19-associated autoimmune processes, and highlights the importance of further investigation into immune-mediated cytopenias secondary to infectious agents. However, readers and researchers are cautioned, as they should ensure sufficient laboratory testing is performed and reported to establish a definitive diagnosis of an autoimmune process, particularly when an unusual condition is in question." @default.
• W4379141146 created "2023-06-03" @default.
• W4379141146 creator A5019417574 @default.
• W4379141146 date "2023-06-01" @default.
• W4379141146 modified "2023-10-16" @default.
• W4379141146 title "Autoimmune hemolytic anemia, COVID-19, and the importance of a complete immunohematologic evaluation" @default.
• W4379141146 cites W2579947954 @default.
• W4379141146 cites W2994304950 @default.
• W4379141146 cites W3036210646 @default.
• W4379141146 cites W4200077404 @default.
• W4379141146 cites W4306630452 @default.
• W4379141146 cites W4362736794 @default.
• W4379141146 doi "https://doi.org/10.1016/j.jiac.2023.06.001" @default.
• W4379141146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37271340" @default.
• W4379141146 hasPublicationYear "2023" @default.
• W4379141146 type Work @default.
• W4379141146 citedByCount "0" @default.
• W4379141146 crossrefType "journal-article" @default.
• W4379141146 hasAuthorship W4379141146A5019417574 @default.
• W4379141146 hasBestOaLocation W43791411461 @default.
• W4379141146 hasConcept C116675565 @default.
• W4379141146 hasConcept C126322002 @default.
• W4379141146 hasConcept C159047783 @default.
• W4379141146 hasConcept C203014093 @default.
• W4379141146 hasConcept C2777385706 @default.
• W4379141146 hasConcept C2778248108 @default.
• W4379141146 hasConcept C2779134260 @default.
• W4379141146 hasConcept C3006700255 @default.
• W4379141146 hasConcept C3007834351 @default.
• W4379141146 hasConcept C3008058167 @default.
• W4379141146 hasConcept C524204448 @default.
• W4379141146 hasConcept C71924100 @default.
• W4379141146 hasConcept C89623803 @default.
• W4379141146 hasConceptScore W4379141146C116675565 @default.
• W4379141146 hasConceptScore W4379141146C126322002 @default.
• W4379141146 hasConceptScore W4379141146C159047783 @default.
• W4379141146 hasConceptScore W4379141146C203014093 @default.
• W4379141146 hasConceptScore W4379141146C2777385706 @default.
• W4379141146 hasConceptScore W4379141146C2778248108 @default.
• W4379141146 hasConceptScore W4379141146C2779134260 @default.
• W4379141146 hasConceptScore W4379141146C3006700255 @default.
• W4379141146 hasConceptScore W4379141146C3007834351 @default.
• W4379141146 hasConceptScore W4379141146C3008058167 @default.
• W4379141146 hasConceptScore W4379141146C524204448 @default.
• W4379141146 hasConceptScore W4379141146C71924100 @default.
• W4379141146 hasConceptScore W4379141146C89623803 @default.
• W4379141146 hasLocation W43791411461 @default.
• W4379141146 hasLocation W43791411462 @default.
• W4379141146 hasLocation W43791411463 @default.
• W4379141146 hasOpenAccess W4379141146 @default.
• W4379141146 hasPrimaryLocation W43791411461 @default.
• W4379141146 hasRelatedWork W3017171836 @default.
• W4379141146 hasRelatedWork W3020672184 @default.
• W4379141146 hasRelatedWork W3025176011 @default.
• W4379141146 hasRelatedWork W3027835066 @default.
• W4379141146 hasRelatedWork W3032320397 @default.
• W4379141146 hasRelatedWork W3033635008 @default.
• W4379141146 hasRelatedWork W3152606407 @default.
• W4379141146 hasRelatedWork W4280491013 @default.
• W4379141146 hasRelatedWork W4308017287 @default.
• W4379141146 hasRelatedWork W3107152225 @default.
• W4379141146 isParatext "false" @default.
• W4379141146 isRetracted "false" @default.
• W4379141146 workType "article" @default.